Hologic's $18.3B Take-Private: A PE Deal Masterclass

Blackstone and TPG just closed an $18.3 billion take-private of Hologic on April 7, 2026. The price was $76 per share in cash plus a contingent value right (CVR) worth up to $3 per share. That's a 46 percent premium to Hologic's unaffected share price from May 23, 2025. This deal tells you everything you need to know about how modern PE consortiums operate at scale and why sovereign wealth funds are now sitting alongside blue-chip private equity firms.

On October 21, 2025, Blackstone and TPG announced they would take the medical device maker private. Three quarters of a year later, the deal closed. Shareholders voted 178.8 million votes in favor and only 151,000 against on February 5, 2026. You can read Hologic's full announcement here: https://www.hologic.com/about/press-release/hologic-be-acquired-blackstone-and-tpg-79-share

Deal Structure: How $18.3B Gets Built

Let me break down the capital stack for you. The $76 per share cash came straight from the deal financing. Here's how the sponsors funded it.

Equity check: Blackstone and TPG together put down roughly $4.5 billion to $5 billion in equity (I'm using the enterprise value and debt stack to back into this). Abu Dhabi Investment Authority (ADIA, $1.11 trillion in assets under management) and Singapore's Government Investment Corporation (GIC, approximately $770 billion plus in AUM) came in as minority equity co-investors. Blackstone's retail-accessible PE vehicle BXPE (which has a $2 billion net asset value) also held a slice.

Debt stack: $9.5 billion in first-lien debt, $2.0 billion in second-lien debt, and a $750 million revolver. That's $12.25 billion in total gross debt. Hologic had $2.2 billion in cash on the balance sheet at close, which reduced net debt. The math: $18.3 billion enterprise value minus $2.2 billion cash minus equity pieces equals the debt requirement. The sponsors used a standard 1.5x to 1.7x levered recapitalization structure.

Deal Structure Why Sovereign Wealth Co-Invests (ADIA, GIC) and What It Signals

Five years ago, you would have seen a pure Blackstone-TPG bilateral deal. Today, you see sovereign wealth funds sitting in the equity check alongside them. I see this trend every month now. ADIA and GIC didn't grab scraps. They took meaningful minority positions. This matters to you as an accredited investor because it tells you where the smartest institutional capital is parking dry powder.

Sovereign wealth funds have three advantages over traditional PE firms. First, they have infinite capital patience. ADIA is backed by Abu Dhabi's oil wealth. GIC answers to Singapore's government. Neither faces LP redemption risk or 10-year fund timelines. Second, they can hold for 15, 20, even 25 years if the asset is right. Hologic isn't getting flipped in five years. Third, they add geopolitical connectivity and operational heft that pure PE can't replicate.

Why did they invest here? Hologic owns the women's health and diagnostics markets. It manufactures 3D mammography systems, cervical cancer screening platforms, and molecular diagnostics. These are essential diagnostic tools. Governments care about cancer screening penetration. ADIA and GIC were betting that a decade of Blackstone operational support plus access to Middle Eastern and Asian healthcare systems equals real value creation.

The Healthcare PE Thesis: Why Firms Like Blackstone Are Targeting Public Health Companies

Here's what Blackstone and TPG saw. Hologic was trading at roughly 14x EBITDA when they announced the deal. Similar healthcare companies with comparable growth rates and margins were trading at 16x to 18x EBITDA. The stock was depressed because public markets had rotated away from non-AI healthcare hardware. Multibagger semiconductors and software got the ink. Boring diagnostic equipment didn't.

Post-pandemic, public health companies hit an air pocket. The market rewarded pure-play biotech, fertility platforms, and telehealth. It punished hardware makers. Hologic's core breast diagnostics business was actually firing on all cylinders. Revenue growth was steady. Operating margins were fat. The company just looked unfashionable.

Blackstone's thesis was simple: buy the mispricing, take the company private to remove quarterly earnings pressure, run efficient operations for five to seven years, and either IPO the company again or sell it to a larger healthcare conglomerate. The CVR gave public equity holders a piece of the upside if execution went really well. It's a clean play.

CVRs Explained: What the Extra $3 Per Share Actually Means

Let's talk about the CVR because this is where accredited investors usually misunderstand the deal.

The CVR is worth up to $3 per share. It breaks into two $1.50 installments. The first $1.50 pays out if Hologic's Breast Health revenue in fiscal 2026 exceeds a specific threshold. The second $1.50 pays out if Breast Health revenue in fiscal 2027 exceeds another threshold. Those thresholds haven't been disclosed publicly, but I can infer they're pitched at 8 to 10 percent revenue growth annually.

Here's the reality of CVRs: historically, only about one-third of CVRs ever pay anything. Two-thirds of deal targets miss the revenue thresholds and public shareholders get nothing beyond the cash price. The average CVR pays out about 40 to 50 cents on the dollar of its stated maximum value.

Why would Blackstone and TPG offer a CVR at all? Because their underwriting showed Breast Health revenue growth was highly achievable. They wanted to buy cheap but didn't want to fight with shareholders on price. A CVR smooths that negotiation. It says to public equity: "We're buying at a modest premium to where you were trading, but we believe we can grow the business and you'll participate in that upside." It worked. Shareholders approved it.

How Accredited Investors Access Deals Like This

You're reading this and asking: can I get into the next $18 billion PE consortium megadeal?

The answer is yes, but you need to understand the access points.

Direct equity co-investment: You need a relationship with Blackstone or TPG and a check size of at least $25 million to $50 million. ADIA and GIC have those relationships. You probably don't. Yet.

Secondary purchases: You can buy LP stakes in Blackstone PE funds on the secondary market. Firms like Lexington Partners and Coller International broker these sales. You buy at a discount to NAV (usually 10 to 20 percent), inherit the LP terms, and get pro-rata access to future deal flows. That's how many accredited investors build PE exposure.

Retail-accessible PE: BXPE is Blackstone's own retail vehicle. It's a closed-end fund trading on the NYSE. Minimum investment is $2,500. You get indirect exposure to Blackstone deals but not direct control. You pay a 1.5 percent management fee plus incentive fees. It's not the same as being a co-investor with ADIA, but it's real PE exposure.

Feeder funds: Some wealth managers and platforms create feeder vehicles that funnel accredited investor capital into larger PE funds. The minimums are lower (often $250,000 to $500,000) but you're paying layer-on-layer fees.

Secondary platforms: Companies like Forge and EquityZen let you buy stakes in pre-IPO companies and secondary PE positions. The liquidity is imperfect, but you can access PE-backed companies before they go public.

Jeff's Take

The Hologic deal is a masterclass in modern PE execution. It shows you that when you have $1 trillion-plus of capital (Blackstone plus TPG plus ADIA plus GIC), you can identify mispriced public companies, buy them at a reasonable premium, and create a financing structure that attracts institutional co-investors without blowing up leverage.

It also shows you that the days of pure bilateral PE deals are over. Sovereign wealth funds are now the co-pilot on every big healthcare, infrastructure, and energy deal above $10 billion. If you're an accredited investor, you should understand how these deals work because they're where the returns are being generated.

The CVR is real money if the company executes. Breast health diagnostics are growing 7 to 9 percent annually. Hologic should hit those thresholds. But don't count on it. Model the deal assuming the $76 is all you get.

If you want PE exposure at your accredited level, start with secondaries or BXPE. Build the relationship with your wealth manager. Get on the co-investment calls when they happen. In five years, when Blackstone IPOs Hologic again or sells it to Johnson & Johnson for $25 billion, you'll understand how you could have been in the room.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.